|
Azilect.(Monoamine oxidase inhibitor for treating the signs and symptoms of idiopathic Parkinson's disease )(Drug overview)
Publication: Internal Medicine News Publication Date: 15-JUN-06 Author: Mechcatie, Elizabeth
|
|
|
|
How to access the full article: Free access to all articles is available courtesy of your local library. To access the full article click the "See the full article" button below. You will need your US library barcode or password.
|
|
|
COPYRIGHT 2006 International Medical News Group
Azilect
(rasagiline, Teva Pharmaceuticals)
An irreversible monoamine oxidase (MAO) inhibitor for treating the signs and symptoms of idiopathic Parkinson's disease as initial monotherapy and as adjunct therapy to levodopa.
* Recommended Dosage: For monotherapy, 1 mg once daily. As an adjunct, 0.5 mg once daily, or 1 mg once daily if...
Read the full article for free courtesy of your local library.
|
|
|
|
 |
| More Articles from Internal Medicine News |
CDC advises routine preconception counseling, with insurance coverage....
June 15, 2006
|
Novel smoking cessation drug helped 44% quit.
June 15, 2006
|
Are tobacco quitlines effective?
June 15, 2006
|
Enzyme tied to success in quitting smoking.
June 15, 2006
|
Paxil label to warn of suicide risk in adults.(Paroxetine)(Drug overvi...
June 15, 2006
|
|
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
